Cargando…

Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker–based immunotherapy

Immune checkpoint blockers (ICBs) have shown great promise at harnessing immune system to combat cancer. However, only a fraction of patients can directly benefit from the anti–programmed cell death protein 1 (aPD1) therapy, and the treatment often leads to immune-related adverse effects. In this co...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Feihu, Xu, Dongqing, Su, Hao, Zhang, Weijie, Sun, Xuanrong, Monroe, Maya K., Chakroun, Rami W., Wang, Zongyuan, Dai, Wenbing, Oh, Richard, Wang, Han, Fan, Qin, Wan, Fengyi, Cui, Honggang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239700/
https://www.ncbi.nlm.nih.gov/pubmed/32490201
http://dx.doi.org/10.1126/sciadv.aaz8985
_version_ 1783536742085689344
author Wang, Feihu
Xu, Dongqing
Su, Hao
Zhang, Weijie
Sun, Xuanrong
Monroe, Maya K.
Chakroun, Rami W.
Wang, Zongyuan
Dai, Wenbing
Oh, Richard
Wang, Han
Fan, Qin
Wan, Fengyi
Cui, Honggang
author_facet Wang, Feihu
Xu, Dongqing
Su, Hao
Zhang, Weijie
Sun, Xuanrong
Monroe, Maya K.
Chakroun, Rami W.
Wang, Zongyuan
Dai, Wenbing
Oh, Richard
Wang, Han
Fan, Qin
Wan, Fengyi
Cui, Honggang
author_sort Wang, Feihu
collection PubMed
description Immune checkpoint blockers (ICBs) have shown great promise at harnessing immune system to combat cancer. However, only a fraction of patients can directly benefit from the anti–programmed cell death protein 1 (aPD1) therapy, and the treatment often leads to immune-related adverse effects. In this context, we developed a prodrug hydrogelator for local delivery of ICBs to boost the host’s immune system against tumor. We found that this carrier-free therapeutic system can serve as a reservoir for extended tumoral release of camptothecin and aPD1 antibody, resulting in an immune-stimulating tumor microenvironment for boosted PD-1 blockade immune response. Our in vivo results revealed that this combination chemoimmunotherapy elicits robust and durable systemic anticancer immunity, inducing tumor regression and inhibiting tumor recurrence and metastasis. This work sheds important light into the use of small-molecule prodrugs as both chemotherapeutic and carrier to awaken and enhance antitumor immune system for improved ICBs therapy.
format Online
Article
Text
id pubmed-7239700
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Association for the Advancement of Science
record_format MEDLINE/PubMed
spelling pubmed-72397002020-06-01 Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker–based immunotherapy Wang, Feihu Xu, Dongqing Su, Hao Zhang, Weijie Sun, Xuanrong Monroe, Maya K. Chakroun, Rami W. Wang, Zongyuan Dai, Wenbing Oh, Richard Wang, Han Fan, Qin Wan, Fengyi Cui, Honggang Sci Adv Research Articles Immune checkpoint blockers (ICBs) have shown great promise at harnessing immune system to combat cancer. However, only a fraction of patients can directly benefit from the anti–programmed cell death protein 1 (aPD1) therapy, and the treatment often leads to immune-related adverse effects. In this context, we developed a prodrug hydrogelator for local delivery of ICBs to boost the host’s immune system against tumor. We found that this carrier-free therapeutic system can serve as a reservoir for extended tumoral release of camptothecin and aPD1 antibody, resulting in an immune-stimulating tumor microenvironment for boosted PD-1 blockade immune response. Our in vivo results revealed that this combination chemoimmunotherapy elicits robust and durable systemic anticancer immunity, inducing tumor regression and inhibiting tumor recurrence and metastasis. This work sheds important light into the use of small-molecule prodrugs as both chemotherapeutic and carrier to awaken and enhance antitumor immune system for improved ICBs therapy. American Association for the Advancement of Science 2020-04-29 /pmc/articles/PMC7239700/ /pubmed/32490201 http://dx.doi.org/10.1126/sciadv.aaz8985 Text en Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). http://creativecommons.org/licenses/by-nc/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license (http://creativecommons.org/licenses/by-nc/4.0/) , which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.
spellingShingle Research Articles
Wang, Feihu
Xu, Dongqing
Su, Hao
Zhang, Weijie
Sun, Xuanrong
Monroe, Maya K.
Chakroun, Rami W.
Wang, Zongyuan
Dai, Wenbing
Oh, Richard
Wang, Han
Fan, Qin
Wan, Fengyi
Cui, Honggang
Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker–based immunotherapy
title Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker–based immunotherapy
title_full Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker–based immunotherapy
title_fullStr Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker–based immunotherapy
title_full_unstemmed Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker–based immunotherapy
title_short Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker–based immunotherapy
title_sort supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker–based immunotherapy
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239700/
https://www.ncbi.nlm.nih.gov/pubmed/32490201
http://dx.doi.org/10.1126/sciadv.aaz8985
work_keys_str_mv AT wangfeihu supramolecularprodrughydrogelatorasanimmuneboosterforcheckpointblockerbasedimmunotherapy
AT xudongqing supramolecularprodrughydrogelatorasanimmuneboosterforcheckpointblockerbasedimmunotherapy
AT suhao supramolecularprodrughydrogelatorasanimmuneboosterforcheckpointblockerbasedimmunotherapy
AT zhangweijie supramolecularprodrughydrogelatorasanimmuneboosterforcheckpointblockerbasedimmunotherapy
AT sunxuanrong supramolecularprodrughydrogelatorasanimmuneboosterforcheckpointblockerbasedimmunotherapy
AT monroemayak supramolecularprodrughydrogelatorasanimmuneboosterforcheckpointblockerbasedimmunotherapy
AT chakrounramiw supramolecularprodrughydrogelatorasanimmuneboosterforcheckpointblockerbasedimmunotherapy
AT wangzongyuan supramolecularprodrughydrogelatorasanimmuneboosterforcheckpointblockerbasedimmunotherapy
AT daiwenbing supramolecularprodrughydrogelatorasanimmuneboosterforcheckpointblockerbasedimmunotherapy
AT ohrichard supramolecularprodrughydrogelatorasanimmuneboosterforcheckpointblockerbasedimmunotherapy
AT wanghan supramolecularprodrughydrogelatorasanimmuneboosterforcheckpointblockerbasedimmunotherapy
AT fanqin supramolecularprodrughydrogelatorasanimmuneboosterforcheckpointblockerbasedimmunotherapy
AT wanfengyi supramolecularprodrughydrogelatorasanimmuneboosterforcheckpointblockerbasedimmunotherapy
AT cuihonggang supramolecularprodrughydrogelatorasanimmuneboosterforcheckpointblockerbasedimmunotherapy